Product Description
Esperance was developing ep-100, an intravenous GnRH Inhibitor for Ovarian Cancer . (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01485848)
Mechanisms of Action: GnRH Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Esperance
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Ovarian Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ESP2009-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2012-03-01 |
2019-03-18 |
Treatments |
|
| ESP2011-002 | P2 |
Completed |
Ovarian Cancer |
2014-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/05/2024 |
News Article |
Introducing Huskie Tools' Groundbreaking 100-Ton Convertible Crimping Head, a Revolutionary Lightweight 100-Ton Convertible Crimping Head for the Power Utility Industry |
|
05/01/2024 |
News Article |
EBONY POWER 100 RETURNS |
|
04/24/2024 |
PubMed |
Immunomodulation of Ethyl pyruvate on gestational diabetes mellitus in Mice; The impact on Th17/Treg balance. |
|
04/23/2024 |
News Article |
Global Architecture & Design Firm, Corgan, Joins the Climate Group |
|
01/16/2024 |
News Article |
DFI To Present Latest Innovations Alongside Partner Dynalog at Embedded Tech India Expo 2024 |
|
06/29/2023 |
PubMed |
Peritoneal Dialysis in Italy: the 8th GPDP-SIN census 2022. |
|
06/27/2023 |
PubMed |
Simultaneous determination of phenols in the four main original plants of the famous traditional Chinese medicine Shihu by pressurized capillary electrochromatography. |